Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019

Background: Germany is a low prevalence country for hepatitis B virus (HBV) infection with higher prevalence in vulnerable groups. The number of treated chronic hepatitis B (CHB) patients is unknown. We aimed to determine the number of CHB patients treated with nucleos(t)ide analogs (NUCs), the trea...

Full description

Bibliographic Details
Main Authors: Anna Maisa, Christian Kollan, Matthias an der Heiden, Florian van Bömmel, Markus Cornberg, Stefan Mauss, Heiner Wedemeyer, Daniel Schmidt, Sandra Dudareva
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Public Health
Subjects:
hepatitis B
nucleos(t)ide therapy
therapy costs
treatment guidelines
treatment gap
hepatitis elimination
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2021.667253/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2021.667253/full

Similar Items